Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Lumbrokinase

Lumbrokinase (Earthworm Protein Extract) · also known as Lumbrokinase, Earthworm protein, Specific fibrinolytic enzyme fraction, Boluoke

Lumbrokinase is extracted from the red earthworm and is a group of polypeptides with serine protease activity. A human randomized trial observed higher t-PA activity and D-dimer and lower fibrinogen, but how much of the intact active enzyme enters the blood after oral intake has not been established.

Typical dose: Standardized lumbrokinase products are often labeled at about 600,000–1,200,000 U of activity, taken 1–2 times daily with warm water, 1 hour before meals or at bedtime. Activity units are not necessarily interchangeable between products, so follow the label of the specific product.
Absorption and forms: Lumbrokinase is a large protease, and whether it reaches the blood in intact, active form after oral intake is not established. Enteric coating and taking it on an empty stomach are often described as important in common claims, but these are not confirmed requirements, and they cannot guarantee complete absorption.

Clinical uses and human evidence

Heart attack, stroke and other cardiovascular events

Mixed resultsGrade C · Preliminary evidence
Studies (1)
  1. Cao 2013 · Chin Med J (Engl) · RCT · n=310 — Oral fibrinogen-depleting agent lumbrokinase for secondary ischemic stroke prevention: results from a multicenter, randomized, parallel-group and controlled clinical trial

Mechanisms of action

Fibrin-specific breakdown and activation of the endogenous fibrinolytic system

★★★★☆Mechanism evidence: grade APrimary target

Lumbrokinase can act on fibrin. A human randomized study observed higher t-PA activity and D-dimer and lower fibrinogen, so fibrinolysis-related human markers did change. However, fibrin breakdown in vitro does not show that the intact enzyme directly breaks up microthrombi in humans, and the contribution of direct enzymatic cleavage is not established.

References (2)
  1. Jin et al. 2000 · Randomized controlled study in 51 people: t-PA activity and D-dimer rose and fibrinogen fell in the lumbrokinase group
  2. Cao et al. 2013 · Multicenter randomized study: the oral preparation can lower patients’ fibrinogen; the study used an open-label design

Platelet-activating factor (PAF) antagonism and improved microcirculatory rheology

★★★☆☆Mechanism evidence: grade ASecondary target

In one multicenter study, some patients’ blood and plasma viscosity measures may have improved. This is a change in hemorheology. It does not show that lumbrokinase antagonizes the PAF receptor, and there is currently no evidence that it specifically occupies PAF receptors in humans.

References (2)
  1. Cao et al. 2013 · Multicenter randomized study: reported changes in patients’ blood and plasma viscosity measures
  2. No direct study found in literature search · Conclusion: no reliable evidence that lumbrokinase specifically occupies PAF receptors in humans

Safety and drug interactions

Do not use it in severe bleeding disorders, active intracranial bleeding, or within 2 weeks before or after major surgery. Combining it with warfarin or other anticoagulants, antiplatelet drugs, nattokinase or ginkgo leaf preparations may raise bleeding risk, and a doctor should assess this. Warfarin can be monitored with prothrombin time (PT/INR), but PT/INR does not reliably reflect the anticoagulant strength of all direct oral anticoagulants.

Additive bleeding risk

Has fibrinolytic activity. Each of these has a mild antiplatelet or fibrinolytic effect. Alone, the effect is usually small, but when several are combined, the tendency to bleed becomes more noticeable. Stop them 1–2 weeks before surgery or a tooth extraction, and watch for gum bleeding or more bruising.

Open in the interactive app ›